| Literature DB >> 32974579 |
Michaël Desjardins1,2, Brigitte Lefebvre3, Christian Lavallée1,4, Annie-Claude Labbé1,4, Florian Mauffrey3, Irene Martin5, Jean Longtin1,3, Claude Fortin1,2.
Abstract
INTRODUCTION: The correlation of antimicrobial susceptibility testing (AST) between agar dilution and gradient diffusion for Neisseria gonorrhoeae is not well established, especially in strains with high MICs. AIM: The objective of this study was to evaluate the accuracy of gradient diffusion for N. gonorrhoeae .Entities:
Keywords: Neisseria gonorrhoeae; antimicrobial susceptibility testing; gradient diffusion
Year: 2020 PMID: 32974579 PMCID: PMC7494190 DOI: 10.1099/acmi.0.000116
Source DB: PubMed Journal: Access Microbiol ISSN: 2516-8290
Results of antimicrobial susceptibility testing using agar dilution (n=50)
|
Number of isolates according to MIC (μg ml–1) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
<0.03 |
0.03 |
0.06 |
0.12 |
0.25 |
0.5 |
1 |
2 |
4 |
8 |
16 |
32 |
64 |
128 |
256 | |
|
Ceftriaxone* |
26 |
7 |
8 |
5 |
– |
2 |
2 |
– |
– |
– |
– |
– |
– |
– |
– |
|
Cefixime* |
22 |
9 |
3 |
2 |
5 |
5 |
– |
4 |
– |
– |
– |
– |
– |
– |
– |
|
Azithromycin† |
– |
– |
4 |
4 |
13 |
12 |
2 |
6 |
2 |
6 |
– |
– |
– |
1 |
– |
|
Tetracycline‡ |
– |
– |
– |
2 |
5 |
11 |
9 |
20 |
– |
1 |
2 |
– |
– |
– |
– |
|
Fosfomycin§ |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
19 |
27 |
3 |
1 |
– |
*Susceptible, ≤0.25 µg ml−1; non-susceptible, ≥0.5 µg ml−1.
†Susceptible, ≤1 µg ml−1; non-susceptible, ≥2 µg ml−1.
‡Susceptible, ≤0.25 µg ml−1; intermediate, 0.5–1 µg ml−1; resistant, ≥2 µg ml−1.
§No interpretative criteria have been published by the CLSI.
Essential (EA) and category agreements (CA) of gradient diffusion versus agar dilution for different combinations of antimicrobial strips and culture media (n=50).
|
Alere |
bioMérieux | ||||
|---|---|---|---|---|---|
|
EA (%) |
CA (%) |
EA (%) |
CA (%) | ||
|
Ceftriaxone |
CLSI |
86 |
100 |
94 |
100 |
|
BD |
98 |
100 |
98 |
100 | |
|
Oxoid |
98 |
100 |
98 |
100 | |
|
Cefixime |
CLSI |
90 |
88 |
92 |
90 |
|
BD |
98 |
98 |
100 |
96 | |
|
Oxoid |
98 |
92 |
94 |
94 | |
|
Azithromycin |
CLSI |
82 |
88 |
80 |
92 |
|
BD |
90 |
90 |
94 |
94 | |
|
Oxoid |
94 |
96 |
96 |
98 | |
|
Tetracycline |
CLSI |
80 |
40 |
86 |
38 |
|
BD |
96 |
76 |
96 |
62 | |
|
Oxoid |
82 |
52 |
82 |
38 | |
|
Fosfomycin |
CLSI |
88 |
– |
92 |
– |
|
BD |
96 |
– |
98 |
– | |
|
Oxoid |
80 |
– |
96 |
– | |
CLSI: GC agar base with 1 % defined growth supplement
na, not applicable.
Rates of minor errors (mE), major errors (ME) and very major errors (VME)
|
Alere |
Biomérieux | ||||||
|---|---|---|---|---|---|---|---|
|
mE,
|
ME,
|
VME,
|
mE,
|
ME,
|
VME,
| ||
|
Ceftriaxone |
CLSI |
– |
0/46 (0) |
0/4 (0) |
– |
0/46 (0) |
0/4 (0) |
|
BD |
– |
0/46 (0) |
0/4 (0) |
– |
0/46 (0) |
0/4 (0) | |
|
Oxoid |
– |
0/46 (0) |
0/4 (0) |
– |
0/46 (0) |
0/4 (0) | |
|
Cefixime |
CLSI |
– |
2/41 (4.9) |
4/9 (44.4) |
– |
0/41 (0) |
5/9 (55.6) |
|
BD |
– |
1/41 (2.4) |
0/9 (0) |
– |
0/41 (0) |
2/9 (22.2) | |
|
Oxoid |
– |
0/41 (0) |
4/9 (44.4) |
– |
0/41 (0) |
3/9 (33.3) | |
|
Azithromycin |
CLSI |
– |
0/35 (0) |
6/15 (40) |
– |
1/35 (2.9) |
3/15 (20) |
|
BD |
– |
0/35 (0) |
5/15 (33.3) |
– |
0/35 (0) |
3/15 (20) | |
|
Oxoid |
– |
0/35 (0) |
2/15 (16.7) |
– |
0/35 (0) |
1/15 (6.7) | |
|
Tetracycline |
CLSI |
29/50 (58) |
0/7 (0) |
1/23 (4.3) |
31/50 (62) |
0/7 (0) |
0/23 (0) |
|
BD |
11/50 (22) |
0/7 (0) |
1/23 (4.3) |
18/50 (36) |
0/7 (0) |
1/23 (4.3) | |
|
Oxoid |
24/50 (48) |
0/7 (0) |
0/23 (0) |
30/50 |
0/7 (0) |
1/23 (4.3) | |
Reproducibility of gradient diffusion versus agar dilution for different combinations of antimicrobial strips and culture media
|
Alere, Reproducibility, |
Biomerieux. Reproducibility, | ||
|---|---|---|---|
|
Ceftriaxone |
CLSI |
14/15 (93.3) |
15/15 (100) |
|
BD |
15/15 (100) |
15/15 (100) | |
|
Oxoid |
14/15 (93.3) |
15/15 (100) | |
|
Cefixime |
CLSI |
15/15 (100) |
15/15 (100) |
|
BD |
15/15 (100) |
15/15 (100) | |
|
Oxoid |
15/15 (100) |
14/15 (93.3) | |
|
Azithromycin |
CLSI |
14/15 (93.3) |
13/15 (86.7) |
|
BD |
15/15 (100) |
15/15 (100) | |
|
Oxoid |
15/15 (100) |
15/15 (100) | |
|
Tetracycline |
CLSI |
15/15 (100) |
15/15 (100) |
|
BD |
15/15 (100) |
15/15 (100) | |
|
Oxoid |
15/15 (100) |
15/15 (100) | |
|
Fosfomycin |
CLSI |
14/15 (93.3) |
14/15 (93.3) |
|
BD |
15/15 (100) |
15/15 (100) | |
|
Oxoid |
15/15 (100) |
15/15 (100) | |